Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939314 · ClinicalTrials.gov registry record · Phase 3
Sphenopalatine Nerve Block for Headache Tx360
A Phase 3 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT01939314 is a Phase 3 study that has completed, run by Indiana University. The registered enrollment target is 93 participants.
The verdict
NCT01939314, a Phase 3 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.
Interventions
- DRUG Placebo
- DRUG Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01939314
The ClinicalTrials.gov registry entry for NCT01939314 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01939314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01939314 about?
NCT01939314 is a clinical study titled "Sphenopalatine Nerve Block for Headache Tx360". The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.
What is the current status of trial NCT01939314?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2012-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01939314?
The interventions under investigation include: Placebo (DRUG), Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT01939314?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.